Evidence map›Paper›PMID 32080350›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2020

Clinicopathological characteristics of glomeruloid architecture in prostate cancer.

Eva Hollemans, Esther I Verhoef, Chris H Bangma, John Rietbergen, Susanne Osanto, Rob C M Pelger, Tom van Wezel, Henk van der Poel, Elise Bekers, Jozien Helleman and 2 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. [Localized prostate cancer].Der Pathologe · 2021
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Eva HollemansDepartment of Pathology, Erasmus MC, University Medical Center, P.O. Box 2040, 3000, Rotterdam, The Netherlands. e.hollemans@erasmusmc.nl.ORCID http://orcid.org/0000-0003-2406-5370
Esther I VerhoefDepartment of Pathology, Erasmus MC, University Medical Center, P.O. Box 2040, 3000, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-2734-0254
Chris H BangmaDepartment of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
John RietbergenDepartment of Urology, Franciscus Gasthuis & Vlietland Hospital, Rotterdam, The Netherlands.
Susanne OsantoDepartment of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Rob C M PelgerDepartment of Urology, Leiden University Medical Center, Leiden, The Netherlands.
Tom van WezelDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0001-5773-7730
Henk van der PoelDepartment of Urology, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Elise BekersDepartment of Pathology, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Jozien HellemanDepartment of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Monique J RoobolDepartment of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0001-6967-1708
Geert J L H van LeendersDepartment of Pathology, Erasmus MC, University Medical Center, P.O. Box 2040, 3000, Rotterdam, The Netherlands.
Erasmus MC · NLLeiden University Medical Center · NLThe Netherlands Cancer Institute · NLSint Franciscus Gasthuis · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glomeruloid architecture is the least common Gleason 4 growth pattern in prostate adenocarcinoma. Its clinicopathological features and relation with cribriform architecture, which has been recognized as an adverse feature, remains to be established. Our objective was to investigate clinicopathological features of glomeruloid architecture in radical prostatectomies. We reviewed 1064 radical prostatectomy specimens and recorded Grade Group, pT-stage, margin status, Gleason pattern percentages, and growth patterns. Simple and complex glomerulations were distinguished by gland size and intraluminal cribriform protrusions. Clinical endpoint was biochemical recurrence-free survival. Glomerulations were identified in 365 (34%) specimens. In 472 Grade Group 2 patients, 210 (44%) had simple and 92 (19%) complex glomerulations. Complex glomerulations coincided with cribriform architecture more often than simple glomerulations (67% versus 52%; P = 0.01). Men with simple glomerulations had significantly lower prostate specific antigen (PSA) levels (9.7 versus 12.1 ng/ml; P = 0.03), percentage Gleason pattern 4 (19% versus 25%; P = 0.001), extra-prostatic extension (34% versus 50%; P = 0.01), and positive surgical margins (25% versus 39%; P = 0.04) than those with cribriform architecture. Extra-prostatic extension (37%) and positive surgical margins (30%) in men with complex glomerulations resembled those with simple glomeruloid rather than those with cribriform architecture. In multivariate Cox regression analysis adjusted for PSA, pT-stage, margin status, and lymph node metastases, cribriform architecture had independent predictive value for biochemical recurrence-free survival (hazard ratio (HR)) 1.9; 95% confidence interval (CI) 1.2-2.9; P = 0.004), while simple (HR 0.8; 95% CI 0.5-1.2; P = 0.26) and complex (HR 0.9; 95% CI 0.5-1.6; P = 0.67) glomerulations did not. Both simple and complex glomeruloid architecture are associated with better outcome than cribriform architecture in Grade Group 2 prostate cancer patients. Therefore, glomeruloid pattern and particularly complex glomerulations should not be classified as a cribriform growth pattern variant in radical prostatectomy specimens.

Indexed as

AdenocarcinomaAgedHumansMaleMiddle AgedNeoplasm GradingProstatic Neoplasms

Identifiers

PMID32080350
OpenAlexW3007398428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.